J A Kemp Partner Promotions 2023

We are pleased to announce that our associates James Cracknell, Lizzie Davenport and Lucy Williams have been promoted to partner with effect from 6 April 2023.

James is a member of the firm’s Chemistry and Pharmaceuticals Group and based in the firm’s Oxford office. James joined J A Kemp in 2013 following a period of post-doctoral research in the fields of bioinorganic electrochemistry and single-molecule electrical sensing of biological analytes. James has particular expertise in technology at the interface of chemistry and biotechnology. His experience extends to pharmaceuticals, process chemistry, electrochemistry (including enzyme-based electrochemistry), chemical biology and protein chemistry.

Lizzie qualified as a veterinary surgeon from the University of Edinburgh, before undertaking an Integrated Training Fellowship combining clinical practice with a PhD in immunology at the Babraham Institute, Cambridge. She joined J A Kemp’s Biotechnology and Life Sciences Group in 2013 and is also based in the firm’s Oxford office. Lizzie handles numerous cases relating to immunotherapeutics and vaccines. In particular, Lizzie drafts and prosecutes applications concerning chimeric antigen receptor (CAR) T cells, platforms for priming and stimulating anti-cancer immune responses, and peptide vaccines against endemic and emerging diseases.

Lucy is a member of the firm’s Biotechnology and Life Sciences Group. She joined the firm in 2012 after studying for her PhD as part of the prestigious Wellcome Trust PhD programme in Developmental and Stem Cell biology at the University of Cambridge. Her work is varied in terms of subject matter, including molecular biology, PCR methods, genetic testing and diagnosis, antibodies and biologics, and cancer therapeutics and gene therapy.